Description: Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. The company offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; Aemcolo, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth, as well as Rifamycin for irritable bowel syndrome with diarrhoea; and Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers, or other gastrointestinal mucosal lesions. It also provides ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for the induction and maintenance of procedural sedation; Qolotag, a medical device that enhances the visualisation of lesions during sigmoidoscopies; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Home Page: www.cosmopharma.com
Riverside II
Dublin,
2
Ireland
Phone:
353 1 817 0370
Officers
| Name | Title |
|---|---|
| Mr. Mauro Severino Ajani | Founder & Exec. Chairman |
| Mr. Alessandro E. Della Cha LL.M | CEO & Exec. Director |
| Mr. Ngo Dinh Nhan | Head of R&D - AI & Biomedical IT |
| Mr. Giulio Evangelisti | Head of Production, AI & Biomedical IT |
| Mr. Niall Donnelly | Chief Financial Officer |
| Mr. Marco Lecchi | Chief Operating Officer |
| Mr. Davide Malavasi | Qualified Person & Technical Director |
| Mr. Luigi Longo | Chief Scientific Officer |
| Ms. Hazel Winchester | Head of Investor Relations |
| Mr. Biagio Vigano | Chief People Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 24.5098 |
|---|---|
| Trailing PE: | 30.0873 |
| Price-to-Book MRQ: | 2.1194 |
| Price-to-Sales TTM: | 15.6635 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 292 |